1.
Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease:
Practice guidance from the American Association for the Study of Liver Diseases.
Hepatology 67, 328–357 (2018).
2.
Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis. Hepatology 69, 2672–2682 (2019).
3.
Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver
disease: Systematic review and meta-analysis. Hepatology 65, 1557–1565 (2017).
4.
Christ, A., Lauterbach, M. & Latz, E. Western diet and the immune system: An
inflammatory connection. Immunity 51, 794–811 (2019).
5.
Williams, C. D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy:
A prospective study. Gastroenterology 140, 124–131 (2011).
6.
McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosingsteatohepatitis using paired biopsies: Implications for prognosis and clinical management. J.
Hepatol. 62, 1148–1155 (2015).
7.
Arab, J. P., Arrese, M. & Trauner, M. Recent Insights into the Pathogenesis of Nonalcoholic
Fatty Liver Disease. Annu. Rev. Pathol. Mech. Dis. 13, 321–350 (2018).
8.
Marchesini, G., Petta, S. & Grave, R. D. Diet, weight loss, and liver health in nonalcoholic
fatty liver disease: pathophysiology, evidence, and practice. Hepatology 63, 2032–2043
(2016).
9.
Parthasarathy, G., Revelo, X. & Malhi, H. Pathogenesis of Nonalcoholic Steatohepatitis: An
Overview. Hepatol. Commun. 4, 478–492 (2020).
10.
Cani, P. D. et al. Microbial regulation of organismal energy homeostasis. Nat. Metab. 1, 34–
48
46 (2019).
11.
Levy, M., Kolodziejczyk, A. A., Thaiss, C. A. & Elinav, E. Dysbiosis and the immune
system. Nat. Rev. Immunol. 17, 219–232 (2017).
12.
Bäckhed F, et al. The gut microbiota as an environmental factor that regulates fat storage.
Proc. Natl. Acad. Sci. USA 101, 15718–15723 (2004).
13.
Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Human gut microbes associated with
obesity SI. Nature 444, 1022–1023 (2006).
14.
Tripathi, A. et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev.
Gastroenterol. Hepatol. 15, 397–411 (2018).
15.
Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota.
Nat. Rev. Gastroenterol. Hepatol. 16, 35–56 (2019).
16.
Kolodziejczyk, A. A., Zheng, D., Shibolet, O. & Elinav, E. The role of the microbiome in
NAFLD and NASH. EMBO Mol. Med. 11, 1–13 (2019).
17.
Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH)
patients: A connection between endogenous alcohol and NASH. Hepatology 57, 601–609
(2013).
18.
Mouzaki, M. et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease.
Hepatology 58, 120–127 (2013).
19.
Loomba, R. et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive
Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 25,
1054-1062.e5 (2017).
20.
Krishnan, S. et al. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory
Response in Hepatocytes and Macrophages. Cell Rep. 23, 1099–1111 (2018).
21.
Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD
49
and obesity. Nature 482, 179–185 (2012).
22.
Allaire, J. M. et al. The intestinal epithelium: Central coordinator of mucosal immunity.
Trends Immunol. 39, 677–696 (2018).
23.
Ouellette, A. J. et al. Developmental regulation of cryptdin, a corticostatin/defensin precursor
mRNA in mouse small intestinal crypt epithelium. J. Cell Biol. 108, 1687–1695 (1989).
24.
Jones, D. E. & Bevins, C. L. Paneth cells of the human small intestine express an
antimicrobial peptide gene. J. Biol. Chem. 267, 23216–23225 (1992).
25.
Jones, D. E. & Bevins, C. L. Defensin-6 mRNA in human Paneth cells: implications for
antimicrobia peptides in host defense of the human bowel. FEBS Lett. 315, 187–192 (1993).
26.
Ayabe, T. et al. Secretion of microbicidal α-defensins by intestinal Paneth cells in response
to bacteria. Nat. Immunol. 1, 113–118 (2000).
27.
Yokoi, Y. et al. Paneth cell granule dynamics on secretory responses to bacterial stimuli in
enteroids. Sci. Rep. 9, 2710 (2019).
28.
Masuda, K., Sakai, N., Nakamura, K., Yoshioka, S. & Ayabe, T. Bactericidal activity of
mouse α-defensin cryptdin-4 predominantly affects noncommensal bacteria. J. Innate
Immun. 3, 315–326 (2011).
29.
Wilson, C. L. et al. Regulation of intestinal alpha-defensin activation by the
metalloproteinase matrilysin in innate host defense. Science 286, 113–117 (1999).
30.
Salzman, N. H. et al. Enteric defensins are essential regulators of intestinal microbial
ecology. Nat. Immunol. 11, 76–83 (2010).
31.
Ou, J., Liang, S., Guo, X. K. & Hu, X. α-Defensins promote bacteroides colonization on
mucosal reservoir to prevent antibiotic-induced dysbiosis. Front. Immunol. 11, 2065 (2020).
32.
Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and
human intestinal Paneth cells. Nature 456, 259–263 (2008).
50
33.
Eriguchi, Y. et al. Graft-versus-host disease disrupts intestinal microbial ecology by
inhibiting Paneth cell production of α-defensins. Blood 120, 223–232 (2012).
34.
Eriguchi, Y. et al. Decreased secretion of Paneth cell α-defensins in graft-versus-host
disease. Transpl. Infect. Dis. 17, 702–706 (2015).
35.
Hayase, E. et al. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graftversus-host disease. J. Exp. Med. 214, 3507–3518 (2017).
36.
Hodin, C. M. et al. Reduced Paneth cell antimicrobial protein levels correlate with activation
of the unfolded protein response in the gut of obese individuals. J. Pathol. 225, 276–284
(2011).
37.
Nakamura, K., Sakuragi, N., Takakuwa, A. & Ayabe, T. Paneth cell α-defensins and enteric
microbiota in health and disease. Biosci. Microbiota Food Health 35, 57–67 (2016).
38.
Herlemann, D. P. R. et al. Transitions in bacterial communities along the 2000 km salinity
gradient of the Baltic Sea. ISME J. 5, 1571–1579 (2011).
39.
Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science
using QIIME 2. Nat. Biotechnol. 37, 852–857 (2019).
40.
Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon
data. Nat. Methods 13, 581–583 (2016).
41.
Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 - Approximately maximum-likelihood
trees for large alignments. PLoS One 5, (2010).
42.
Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:
Improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).
43.
Nakamura, K., Sakuragi, N. & Ayabe, T. A monoclonal antibody-based sandwich enzymelinked immunosorbent assay for detection of secreted α-defensin. Anal. Biochem. 443, 124–
131 (2013).
51
44.
Yokoi, Y., Adachi, T., Sugimoto, R., Kikuchi, M. & Ayabe, T. Biochemical and Biophysical
Research Communications Simultaneous real-time analysis of Paneth cell and intestinal stem
cell response to interferon- g by a novel stem cell niche tracking method. Biochem. Biophys.
Res. Commun. 545, 14–19 (2021).
45.
Shimizu, Y. et al. Paneth cell α-defensin misfolding correlates with dysbiosis and ileitis in
Crohn’s disease model mice. Life Sci. Alliance 3, e201900592 (2020).
46.
Kim, K. et al. Mitogenic Influence of Human R-Spondin1 on the Intestinal Epithelium. 309,
1256–1260 (2005).
47.
Takashima, S. et al. The Wnt agonist R-spondin1 regulates systemic graft-versus-host
disease by protecting intestinal stem cells. J. Exp. Med. 208, 285–294 (2011).
48.
Tomisawa, S. et al. Efficient production of a correctly folded mouse α-defensin, cryptdin-4,
by refolding during inclusion body solubilization. Protein. Expr. Purif. 112, 21–28 (2015).
49.
Fasano, A. et al. Zonulin, a newly discovered modulator of intestinal permeability, and its
expression in coeliac disease. Lancet 355, 1518–1519 (2000).
50.
Selsted, M. E., Miller, S. I., Henschen, A. H. & Ouellette, A. J. Enteric defensins: Antibiotic
peptide components of intestinal host defense. J. Cell Biol. 118, 929–936 (1992).
51.
Wehkamp, J. & Stange, E. F. An Update Review on the Paneth Cell as Key to Ileal Crohn’s
Disease. Front. Immunol. 11, (2020).
52.
Ouellette, A. J. et al. Mouse Paneth cell defensins: Primary structures and antibacterial
activities of numerous cryptdin isoforms. Infect. Immun. 62, 5040–5047 (1994).
53.
Suzuki, K. et al. Decrease of α‑defensin impairs intestinal metabolite homeostasis via
dysbiosis in mouse chronic social defeat stress model. Sci. Rep. 11, 9915 (2021).
54.
Shanahan, M. T., Tanabe, H. & Ouellette, A. J. Strain-specific polymorphisms in paneth cell
α-defensins of C57BL/6 mice and evidence of vestigial myeloid α-defensin pseudogenes.
52
Infect. Immun. 79, 459–573 (2011).
55.
Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term
outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389397.e10 (2015).
56.
Younossi, Z. M. et al. Nonalcoholic steatofibrosis independently predicts mortality in
nonalcoholic fatty liver disease. Hepatol. Commun. 1, 421–428 (2017).
57.
Charlton, M. et al. Fast food diet mouse: novel small animal model of NASH with
ballooning, progressive fibrosis, and high physiological fidelity to the human condition. AJP
Gastrointest. Liver Physiol. 301, G825–G834 (2011).
58.
Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in nonalcoholic steatohepatitis. Int. J. Exp. Pathol. 94, 93–103 (2013).
59.
Del Chierico, F. et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease
and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65,
451–464 (2017).
60.
Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut
dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764–775
(2016).
61.
Schmidt, T. S. B., Raes, J. & Bork, P. The Human Gut Microbiome: From Association to
Modulation. Cell 172, 1198–1215 (2018).
62.
Ouellette, A. J. Paneth cell α-defensins in enteric innate immunity. Cell. Mol. Life Sci. 68,
2215–2229 (2011).
63.
Sicard, J. F., Bihan, G. Le, Vogeleer, P., Jacques, M. & Harel, J. Interactions of intestinal
bacteria with components of the intestinal mucus. Front. Cell. Infect. Microbiol. 7, 387
(2017).
53
64.
Jiang, T. et al. Lactobacillus Mucosae strain promoted by a high-fiber diet in genetic obese
child alleviates lipid metabolism and modifies gut microbiota in ApoE-/- mice on a western
diet. Microorganisms 8, 1225 (2020).
65.
Ringel, Y. et al. High throughput sequencing reveals distinct microbial populations within
the mucosal and luminal niches in healthy individuals. Gut Microbes 6, 173–181 (2015).
66.
Pereira, F. C. et al. Rational design of a microbial consortium of mucosal sugar utilizers
reduces Clostridiodes difficile colonization. Nat. Commun. 11, 5104 (2020).
67.
Wu, M. et al. The Differences between luminal microbiota and mucosal microbiota in mice.
J. Microbiol. Biotechnol. 30, 287–295 (2020).
68.
Meyer-Hoffert, U. et al. Secreted enteric antimicrobial activity localises to the mucus surface
layer. Gut 57, 764–771 (2008).
69.
Smith, B. J. et al. Changes in the gut microbiota and fermentation products associated with
enhanced longevity in acarbose-treated mice. BMC Microbiol. 19, 130 (2018)
70.
Volk, J. K. et al. The Nlrp6 inflammasome is not required for baseline colonic inner mucus
layer formation or function. J. Exp. Med. 216, 2602–2618 (2019).
71.
Weitkunat, K. et al. Short-chain fatty acids and inulin, but not guar gum, prevent dietinduced obesity and insulin resistance through differential mechanisms in mice. Sci. Rep. 7,
1–13 (2017).
72.
Cazanave, S. C. et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J. Biol.
Chem. 286, 39336–39348 (2011).
73.
Horne, R. G. et al. High fat-high fructose diet-induced changes in the gut microbiota
associated with dyslipidemia in Syrian hamsters. Nutrients 12, 1–20 (2020).
74.
Hanada, T. et al. The Atg12-Atg5 conjugate has a novel E3-like activity for protein
lipidation in autophagy. J. Biol. Chem. 282, 37298–37302 (2007).
54
75.
Ni, H. et al. Nrf2 promotes the development of fibrosis and tumorigenesis in mice with
defective hepatic autophagy. J. Hepatol. 61, 617–625 (2014).
76.
Takakuwa, A. et al. Butyric acid and leucine induce α-defensin secretion from small
intestinal Paneth cells. Nutrients 11, 2817 (2019).
77.
Ayabe, T. et al. Modulation of mouse paneth cell α-defensin secretion by mIKCa1, a Ca2+activated, intermediate conductance potassium channel. J. Biol. Chem. 277, 3793–3800
(2002).
78.
Clarke, L. L. et al. Abnormal Paneth cell granule dissolution and compromised resistance to
bacterial colonization in the intestine of CF mice. Am. J. Physiol. Gastrointest. Liver Physiol.
286, 1050–1058 (2004).
79.
Nashida, T., Imai, A. & Shimomura, H. Relation of Rab26 to the amylase release from rat
parotid acinar cells. Arch. Oral Biol. 851, 89–95 (2006).
80.
Li, S. K., Zhu, D., Gaisano, H. Y. & Brubaker, P. L. Role of vesicle-associated membrane
protein 2 in exocytosis of glucagon-like peptide-1 from the murine intestinal L cell.
Diabetologia 57, 809–818 (2014).
81.
Dong, Y., Wan, Q., Yang, X., Bai, L. & Xu, P. Interaction of Munc18 and Syntaxin in the
regulation of insulin secretion. Biochem. Biophys. Res. Commun. 360, 609–614 (2007).
82.
Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β
production. Nature 456, 264–268 (2008).
83.
Bansal, M. et al. Optineurin promotes autophagosome formation by recruiting the
autophagy-related Atg12-5-16L1 complex to phagophores containing the Wipi2 protein. J.
Biol. Chem. 293, 132–147 (2018).
84.
Wang, J. et al. N-3 polyunsaturated fatty acid-enriched lipid emulsion improves Paneth cell
function via the IL-22/Stat3 pathway in a mouse model of total parenteral nutrition. Biochem.
55
Biophys. Res. Commun. 490, 253–259 (2017).
85.
Lee, Y. S. et al. Microbiota-Derived Lactate Accelerates Intestinal Stem-Cell-Mediated
Epithelial Development. Cell Host Microbe 24, (2018).
86.
Ulmasov, B. et al. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses
Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol. Commun. 3, 246–261
(2019).
56
Acknowledgements
I am grateful to many people who supported me, so that I was able to start my doctoral study and
continue my all research. First of all, I would like to thank the people who strongly supported me.
I would like to express my deepest gratitude to Professor Emeritus Tokiyoshi Ayabe for invaluable
advice and guidance throughout all of my research activities. I thank for his great patience and guiding
me to the appropriate way to reach my final goal.
I sincerely and deeply appreciate Professor Kiminori Nakamura for teaching me the fundamentals of
all experimental methods, ways of thinking, and attitudes toward research. I thank for devoting a great
deal of his time, intelligence, and emotional support to me a lot. I also deeply appreciate Assistant
Professor Yuki Yokoi and Dr. Yu Shimizu in the Innate Immunity Laboratory for courteous guidance
and support throughout my research.
I would like to thank Professor Tomoyasu Aizawa for continuous support of my research as an
important collaborator as well as the associate examiner of the thesis. I also thank Associate Professor
Ryota Uehara for supporting my research as associate examiner of the thesis. I sincerely appreciate
Professor Andre J Ouellette at Kech School of Medicine in University of Southern California for
precise advice and constructive discussions. I would like to thank Ms. Aiko Kuroishi and Ms. Mutsuko
Tanaka who provided enormous technical support. I thank Ms. Mari Tatsumi who has always helped
me in my entire laboratory life. Finally, I gratitude to all the laboratory members for their support in
continuing and accomplishing this work.
57
...
論文の公開元へ
